CareDx (NASDAQ:CDNA) Stock Rated “Overweight” in New Coverage at Piper Sandler

Piper Sandler assumed coverage on shares of CareDx (NASDAQ:CDNA – Free Report) in a research note released on Wednesday, Marketbeat Ratings reports. The firm issued an overweight rating and a $100.00 price target on the stock.

CDNA has been the subject of a number of other reports. BTIG Research lifted their target price on shares of CareDx from $81.00 to $92.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Weiss Ratings upgraded shares of CareDx from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Monday, August 3rd. HC Wainwright reaffirmed a “neutral” rating and issued a $46.00 price target on shares of CareDx in a report on Friday, July 31st. Finally, Wall Street Zen downgraded shares of CareDx from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.33.

Get Our Latest Stock Analysis on CDNA

CareDx Stock Performance

Shares of NASDAQ CDNA opened at $77.88 on Wednesday. The company has a market cap of $4.09 billion, a PE ratio of 120.92 and a beta of 2.51. The business has a 50-day simple moving average of $66.34 and a two-hundred day simple moving average of $36.70. CareDx has a fifty-two week low of $15.15 and a fifty-two week high of $90.87.

CareDx (NASDAQ:CDNA – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.45. The firm had revenue of $139.36 million for the quarter, compared to the consensus estimate of $121.96 million. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The company’s revenue for the quarter was up 39.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.03 earnings per share. On average, sell-side analysts predict that CareDx will post 1.00 earnings per share for the current fiscal year.

Insider Buying and Selling at CareDx

In other news, CFO Keith Kennedy sold 61,961 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $77.82, for a total value of $4,821,805.02. Following the completion of the transaction, the chief financial officer directly owned 199,147 shares in the company, valued at $15,497,619.54. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On CareDx

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in CareDx during the 2nd quarter worth about $137,219,000. Bamco Inc. NY acquired a new position in shares of CareDx in the 2nd quarter valued at about $55,214,000. Bank of America Corp DE acquired a new position in shares of CareDx in the 2nd quarter valued at about $16,297,000. Palo Alto Investors LP acquired a new position in shares of CareDx in the 2nd quarter valued at about $15,158,295. Finally, Jupiter Topco LLC purchased a new stake in shares of CareDx in the second quarter worth about $9,673,000.

CareDx Company Profile

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Further Reading

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.